Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
(19h)
Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail
(22h)
ARPA-H awards up to $160M to scientists developing custom genetic medicines
(1d)
Chutes & Ladders—Idorsia locks in new CEO after shakeup
(1d)
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
(1d)
Illumina names new commercial, legal chiefs as sequencing business shows signs of stability
(1d)
Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease
(1d)
GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failures
(2d)
FDA halts release of new drug rejection letters while working to formalize policy
(2d)
Why biotech revenue projections ‘won’t look as sunny’ once Trump tax bill hits Medicaid enrollment
(2d)
Prime wins patent fight with Beam to continue work on AATD gene editing therapy
(2d)
Satellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readout
(2d)
Scipher picks up Chemomab’s rheumatoid arthritis drug, Nasdaq listing in all-stock merger
(2d)
Leo Cancer Care secures $65M series D to advance upright radiotherapy system
(2d)
AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre
(3d)
Caidya and Simbec-Orion unite in global CRO combo
(3d)
MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
(3d)
Whitehawk swoops in for five ADCs via development deal with China's Biocytogen
(3d)
Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s
(3d)
Boehringer bags PVT’s viral vector platform for cancer vaccine RD
(3d)
BioPharma Dive
GSK, Hansoh ADC extends survival in lung cancer study
(16h)
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
(19h)
Roche scraps two Ionis-partnered Huntington’s drugs
(1d)
GSK ends brain drug alliance with Alector
(1d)
HHS plan to speed drug research won’t remove ‘self-inflicted’ delays
(1d)
AstraZeneca, Ionis drug fails big heart disease study in major setback
(1d)
AstraZeneca, GSK intensify China ties with Sino Biopharm deals
(2d)
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
(2d)
Oberland pours up to $400M into MeiraGTx eye gene therapies
(3d)
Kailera says obesity pill succeeds in late-stage trial in China
(3d)
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
(3d)
Vera Therapeutics wins FDA nod for closely watched kidney disease drug
(3d)
Gene editing developer Scribe plots an IPO
(4d)
Novartis to acquire ADC developer in a deal worth up to $1.5B
(4d)
Cancer, immune drugmakers dominate VC funding so far in 2026
(4d)
Beyond Boston: Unlikely cities stake biotech claims
(4d)
A PureTech startup banks $180M for a new IPF drug
(1w)
Roche KRAS drug succeeds in head-to-head lung cancer study
(1w)
BridgeBio gets funding for drug launch; United buys into cell therapy
(1w)
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
(1w)
Endpoints News
Apnimed files for IPO as FDA reviews its sleep apnea drug
(10h)
FDA returns to releasing pharma rejection letters with 14 new CRLs
(13h)
FDA rejects Hengrui-Elevar liver cancer drug combo for third time
(14h)
FDA adds 100+ new CDER employees in a quarter for first time since late 2024
(14h)
US biotechs turn secretive as they fear competition from rising Chinese industry
(15h)
German lawmakers pass cost-saving bill that drugmakers say will drive them out
(16h)
Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
(17h)
The data that led Cellular Intelligence to pick up Novo's Parkinson's stem cell therapy
(20h)
Pfizer appoints obesity discovery head; AI startup Xaira makes leadership adjustments
(20h)
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
(1d)
HHS advances plan to pay out Covid-19 vaccine injury claims
(1d)
Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset
(1d)
UK price watchdog recommends against Amgen's Lumakras in lung cancer
(1d)
FDA criticizes Lundbeck for now-deleted webpages on migraine treatment
(1d)
FDA quietly stops releasing CRLs
(1d)
The biggest health tech stories of 2026 — so far
(1d)
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
(1d)
Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing down
(1d)
Catalent to divest UK site; Rottendorf, Evonik announce manufacturing builds
(1d)
GSK walks away from Alector pact as immuno-neurology bet fizzles
(1d)
BioSpace
From sequence to scale: Gene editing’s new era in biologics manufacturing
(16h)
AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
(17h)
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
(17h)
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
(19h)
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
(19h)
Amgen continues to defend Tavneos as global regulatory pressure mounts
(1d)
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
(1d)
Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up
(1d)
Psychedelics surge again as Compass, Definium provide more clinical validation
(1d)
Saol boards FDA’s resubmission boat, armed with new survival data
(1d)
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3
(1d)
GSK abandons Alector after back-to-back neuro stumbles
(1d)
FDA freezes CRL trove as ‘radical transparency’ push hits speedbump
(1d)
Tanabe pens deal to sell plants to Towa in post-buyout pivot
(2d)
Through flux and fluidity, FDA keeps coming back to rare disease
(2d)
Amgen recalls almost 1 million bottles of heart failure drug over quality issue
(2d)
Obesity newcomer Kalohexis makes confidential IPO bid 3 months after spinoff
(2d)
AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical
(2d)
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
(3d)
5 largest VC rounds of H1 2026
(3d)
STAT News
Nominee for key federal health role has a history of questioning vaccines
(12h)
Roche ends Huntington’s gene-silencing programs
(18h)
We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
(18h)
FDA quietly pushes back deadline on electric shock ban
(19h)
How a Boston doctor built a following as a ‘loud and unafraid’ voice in the Trump era
(23h)
New York boys club has a time-tested recipe to protect members’ mental health
(23h)
The primary care crisis paradox
(23h)
Whistleblower takes on health insurance and FDA commissioner candidates
(1d)
Outbreak of diarrhea-causing parasite grows to more than 1,000 cases
(1d)
ARPA-H launches $160 million effort to develop custom gene editing drugs
(1d)
FDA finalists under review
(1d)
Prime wins Beam arbitration, clearing path to clinic
(1d)
We’re reading about FDA commissioner contenders, a heart drug failure, and more
(1d)
OpenEvidence backs study that finds it beats LLMs
(1d)
Who’s going to run the FDA?
(1d)
931 days. The drug approval scandal hiding in plain sight
(1d)
AstraZeneca, Ionis report major trial failure with heart disease drug
(2d)
What happens on ‘MAHA Monday’?
(2d)
The quest to save Grace — and clear the way for rare disease patients everywhere
(2d)
Who benefits from classifying obesity as a disease?
(2d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(2w)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(3w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(2mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(3mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(3mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(3mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(3mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(3mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(3mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(3mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(3mo)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(3mo)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(3mo)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(3mo)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(3mo)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(3mo)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(3mo)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(3mo)
Drug Channels
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(21h)
The Hidden Cost of 340B for Employers and Health Plans
(2d)
The Hidden Cost of 340B for Employers and Health Plans
(2d)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(2w)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(2w)
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(2w)
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(2w)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(2w)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(2w)
The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy
(3w)
The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy
(3w)
Drug Channels News Roundup, Mid-June 2026: Biosimilar Development Barriers, Hospital Specialty Pharmacy Growth, Medicaid Incentives, Drug Pricing Tradeoffs, and the Prescription-Filling Process
(3w)
Drug Channels News Roundup, Mid-June 2026: Biosimilar Development Barriers, Hospital Specialty Pharmacy Growth, Medicaid Incentives, Drug Pricing Tradeoffs, and the Prescription-Filling Process
(3w)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
(3w)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
(3w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care (rerun)
(4w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care (rerun)
(4w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(4w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(4w)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update (rerun)
(1mo)
European Biotechnology Magazine
Roche drops two Huntington’s programmes from Ionis
(23h)
AstraZeneca and Ionis miss in key ATTR-CM trial
(1d)
GSK ends Alector neuroscience deal after trial failures
(1d)
Alchemab extends Series A with £25m from British Business Bank
(2d)
AZ buys ex-China rights to Sino’s COPD drug for $2.1bn
(2d)
Boehringer licenses PVT virus platform for cancer vaccines
(3d)
Graph Therapeutics raises $5m to advance I&I pipeline
(3d)
EG 427 rebrands as Cyllene and cashes in €33m Series C
(4d)
Where will AI actually move the needle in drug discovery?
(5d)
Novartis buys UK ADC biotech Myricx Bio in up to $1.5bn deal
(5d)
Genentech signs $515m breast cancer deal with Astex
(5d)
SLAS Europe 2026 – Recap and Outlook
(5d)
One CSO for two companies
(1w)
AstraZeneca returns to CSPC with $1.77bn kidney deal
(1w)
Oryzon raises €12m to push AML and CNS pipeline
(1w)
Experienced CEO takes over
(1w)
Telum raises €18M to push phage-derived antimicrobials toward clinic
(1w)
Abivax cashes in on investor enthusiasm with €807m raise
(1w)
AlzeCure licenses Alzheimer’s asset to QuantumCell in $2.2bn deal
(1w)
Ipsen’s buying streak continues with €700m Memo deal
(1w)
Drug Hunter
How to “pHLIP” the Script on Drug Delivery
(17h)
ACT-1004-1239
(1d)
TERN-701
(2d)
Getting Large Molecules Into the Brain Through Transferrin Receptor-Mediated Delivery
(3d)
sparsentan
(4d)
avacopan
(1w)
islatravir
(1w)
May 2026 Patent Gazette
(1w)
Boron Neutron Capture Therapy: Precision Radiation With Targeted Delivery
(2w)
Module 5, Section 2: Ligand-Based Design
(2w)
May 2026
(2w)
MRTX1719
(2w)
cleminorexton
(2w)
fluoxetine
(2w)
An ADC Primer for Medicinal Chemists
(3w)
CID-078
(3w)
zasocitinib (TAK-279/NDI-034858)
(3w)
Target- and Ligase-First Use of DCAF16 for TPD
(3w)
Topological Polar Surface Area Cheat Sheet
(3w)
irafamdastat (BMS-986368)
(4w)
Labiotech.EU
Top biotech deals in June 2026
(18h)
Turning cancer cell dependencies into targeted therapies
(23h)
11 biotech companies leading the way in Denmark
(2d)
The hidden innovation system behind drug repurposing
(3d)
Why Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europe
(4d)
The biggest biotech funding rounds in June 2026
(4d)
Novartis’ strategy in 2026: rebuilding the pipeline after Entresto
(1w)
The first PROTAC is here. What comes next in protein degradation?
(1w)
Prague: The up-and-coming biotech hub in Central Europe
(1w)
Rethinking precision oncology drug development: AI and tumor biology for smarter therapeutic programs
(2w)
VIB: fueling research amid EU funding woes
(2w)
“It’s time to Act”: EU biotech to undergo major changes
(2w)
De-risking neurology drug development with better mouse models
(2w)
How human-first datasets are reshaping AI drug discovery
(2w)
Roche, a company built on oncology and diagnostics reinventing its pipeline
(2w)
Bronchiectasis treatment after brensocatib: where the field goes next
(2w)
8 of the most expensive drugs in biopharma: Unraveling the costliest medications
(3w)
The Naming Patterns Behind 12,000 Biotech Companies
(3w)
BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler
(3w)
Eight in vivo CAR T biotechs to follow closely
(3w)
Bio IT World
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(1d)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(2d)
Insilico Medicine Launches Phase III Trial for AI-Developed Drug
(3d)
Digital Brain Twin Tailor-Made for Autism Spectrum Disorder
(4d)
Follow the Money: Inflammatory Bowel Disease Oral Drug, Breast, Colorectal Cancer ADCs, Other Next-Gen, Novel Treatments
(1w)
Anthropic Launches Claude Science, Illumina's Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium
(1w)
SOPHiA GENETICS, Memorial Sloan Kettering Joint Venture, Illumina Launches Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium
(2w)
The Spatial Biology Bottleneck: Why AI Models Fail on Complex Tissue & What Actually Fixes It
(2w)
Every Microbiome Tells a Changeable, Computable Story
(2w)
Notes from the Trenches: A Computational Biologist’s View of Drug Discovery’s Digital Revolution
(3w)
AI Readiness in Pharma – Getting the Foundation Right
(3w)
AI Readiness in Pharma – Getting the Foundation Right
(3w)
AI Readiness in Pharma – Getting the Foundation Right
(3w)
The Invisible Infrastructure: Bio-IT World Panel Warns of a Slow-Motion Crisis in Biomedical Data
(3w)
Microsoft, Ginkgo Collaborate to Demonstrate Lab-in-the-Loop Biology
(4w)
From Automation to Autonomy: How Agentic AI Is Redefining Biopharma’s Digital Workforce
(4w)
Navigating the Perilous Journey from Lab to Market
(1mo)
As AI Reshapes Drug Discovery the Lab Remains the Bottleneck
(1mo)
Federation Plus Fine Tuning: The Push for Federated Learning Models Continues
(1mo)
Trends from the Trenches: AI-Ready Life Sciences Data
(1mo)
GEN News
Macrophage Membrane-Derived Nanoparticles Shows Potential Against Candida Infections
(15h)
Epigenomic Analysis Uncovers New AML Subgroups and Drug Sensitivities
(1d)
Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial
(1d)
Crohn’s Disease Phage Therapy Neutralizes Inflammatory E. coli in Mouse Model
(1d)
Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice
(1d)
Ag Genomics Begins to Bear Fruit
(1d)
Top 10 Best-Selling Drugs 2026
(1d)
Virtual Cells Go Multiscale to Predict Complex Biology
(1d)
Advanced Cell Sorting Balances Precision, Scale, and Simplicity
(1d)
Texas Biomed Enters Into a CRADA with U.S. Dept. of War to Help Protect Against Biological Threats
(1d)
Epitope Editing Strategy Could Enable Less Toxic Stem Cell Transplants
(2d)
Fujifilm Selected with Six Others in FDA PreCheck Pilot Manufacturing Program
(2d)
Interface Mismatches Remain Key Barrier to Continuous Bioprocessing
(2d)
Local PBMC Isolation Enables Four-Hour Processing in San Diego
(2d)
Plant Expression Platforms May Be Better Option for Biopharma in the Global South
(2d)
Perfusion Technologies Gain Momentum in Biomanufacturing
(2d)
Oligonucleotide Therapeutic Industry Readies Itself to Move to the Next Phase
(2d)
Astrocytes Preserve Memory Persistence Through Ankyrin-2 Protein in Mice
(2d)
Novartis to Acquire Myricx Bio for Up to $1.5B, Adding Cancer-Fighting ADC Payload Platform
(3d)
Germline‑Targeting HIV Vaccine Generates Broadly Neutralizing Antibodies in Primates
(3d)
Cure Today
A Simple Calf, Hamstring & Low Back Relief Routine for Patients With Cancer
(2d)
What Patients Should Know About Preparing for Cell Therapy
(2d)
Targeted therapy in Lung Cancer Care: What the Research Shows
(2d)
What the 2026 World Cup Teaches About Hope, Resilience, and Recovery
(2d)
Rob Lowe: Clinical Trials Extended My Grandmother's Life
(3d)
A Simple Flexibility Exercise for Patients with Cancer
(3d)
Finding Clarity: Questions and Answers Through Cancer
(3d)
Practical Considerations, Logistical Burdens, and Support Resources for Metastatic EGFR-Positive NSCLC
(3d)
Treatment Landscape of Late-Stage Metastatic EGFR-Positive NSCLC, Side Effect Education, and Shared Decision-Making
(3d)
Nurses Create Food Pantry to Fight Food Insecurity Among Pediatric Cancer Families
(4d)
Why Cancer Survivors Should Celebrate Every Cancer-Free Anniversary
(4d)
Michelle Monaghan Discusses Skin Cancer Advocacy and Sun Safety
(4d)
Nurse Tackles Food Insecurity to Improve Cancer Patient Outcomes
(6d)
Nursing Leader Drives Equity in Kidney Cancer Clinical Trials
(1w)
When Insurance Delays Cancer Care: Why Patients Must Become Their Own Advocates
(1w)
Clinical Trials Provider Brings Expertise and Compassion to Cancer Care
(1w)
The Cancer Search Bar: Top Pancreatic Cancer Questions Answered
(1w)
From Triple Negative to Triply Positive: A Breast Cancer Survivor's Story of Hope
(1w)
Epkinly Plus Revlimid Improves Progression-Free Survival in Relapsed Diffuse Large B-Cell Lymphoma
(1w)
FDA Approves Tregzi for Patients with Blood Cancer Undergoing Stem Cell Transplant
(1w)
Contract Pharma
The Friday Brief for July 10, 2026: Companies and Facilities Changing Hands
(18h)
Biohaven Announces Scientific Leadership Changes
(18h)
Takara Bio USA President and CEO Carol Lou to Retire, Succeeded by Andrew Farmer
(1d)
WuXi Biologics Drug Substance Manufacturing Facility Passes FDA Pre-License Inspection
(1d)
Securing Reliable U.S. Supply of Complex Oral Solid Dose Manufacturing
(1d)
From Potential to Practical at DIA 2026: Structure Before AI
(1d)
Olon Completes Major Concord Facility Expansion
(1d)
Gattefossé Accelerates Production Ramp-up at Lufkin Facility
(1d)
Teva and Polpharma Biologics Ink Global Biosimilar Agreement
(1d)
Boehringer Ingelheim, BioMed X Form Eye Health Research Team
(1d)
Agilent Expands HPLC Column Portfolio to Enhance Biotherapeutic Analysis
(2d)
OTR Therapeutics, LG Chem Partner to Accelerate Novel Oncology Therapy Development
(2d)
Fujifilm Holly Springs Selected for FDA PreCheck Pilot
(2d)
Autolomous, Cellular Origins Expand Platform Integration, Enabling End-to-End Cell Therapy Manufacturing
(2d)
Symeres and Axxam Name Russell Thomas as CSO
(2d)
Aptamer Group Begins Development of Rapid Test for Bundibugyo Ebola
(2d)
Helix and AstraZeneca Sign Multi-Year Genomics Data Partnership
(2d)
Evonik to Invest $100M in Indiana API Manufacturing Hub
(2d)
Rentschler Biopharma Appoints Dr. Torsten Woehr as CEO
(3d)
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Mfg. Ops
(3d)
Pharma Times
Pluripotent stem cell trial for Huntington’s disease
(1d)
Jascayd gains UK licence for treatment of pulmonary fibrosis
(2d)
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
(3d)
Compass Pathways reports six‑month data confirming durable profile of COMP360
(3d)
Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
(3d)
Wegovy pill launches in UK as first daily oral GLP‑1 for weight management
(4d)
Sofinnova reports Myricx Bio to be acquired by Novartis
(4d)
Francis Crick Institute and Medicines Discovery Catapult open applications for next KQ Labs cohort
(1w)
Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
(1w)
AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project
(1w)
R1 Therapeutics forms advisory board to support advancement of AP306
(1w)
UAE launches first genomics-driven clinical trial to prevent Alzheimer’s disease
(2w)
Viridian wins FDA approval for Lumvoa for thyroid eye disease
(2w)
Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial
(2w)
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer
(2w)
Lundbeck to present new Vyepti and bocunebart data at EAN 2026
(2w)
Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
(2w)
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
(3w)
Cenrifki approved in EU for secondary progressive multiple sclerosis
(3w)
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
(4w)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(3w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(3w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(3w)
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
(3w)
The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate
(3w)
Leveraging Technology to Navigate the New Era of Continuous Organ Distribution
(3w)
InStride Raises $30M to Scale Pediatric Mental Health Support
(3w)
New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug
(3w)
What’s Flowing Beneath the World Cup: How Verily’s Wastewater Monitoring Could Catch the Next Outbreak
(3w)
The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design
(3w)
Healthcare Access Depends on Infrastructure: Why Rural Communities Can’t Afford Fragmentation
(3w)
Natural Selection Will Weed Out the Weak in the Race to Autonomous Healthcare
(3w)
Healthcare AI Beyond the Buzzwords: Ambient, Generative, and Agentic Explained
(3w)
Multicare CFO: Decades of CMS Underpayment is Creating an Unfair Two-Tiered System
(4w)
Elevance Health’s 3 Key Priorities for AI
(4w)
Lilly’s Newly Acquired Drug Shows Promise as Next-Gen Blood Cancer Med
(4w)
Don’t Leave Healthcare’s Greatest Asset Behind on the Road to Interoperability
(4w)
Where Healthcare Data Systems Fail and How to Build Them Better
(4w)
The FDA Opened the Door For Rare Disease Patients — Here’s What It Takes to Walk Through It
(4w)
Why One in Four Americans Is Walking Away from Healthcare
(4w)
Chemical & Engineering News
Memory Lane: Cultivating a right to science education
(11h)
Policy Watch: FDA rejects petition to set PFAS limits in certain foods
(13h)
Chemists get twice the reactivity from a single substitution handle
(16h)
Meet the 2026 CAS Future Leaders
(18h)
What the nose knows
(18h)
C&EN weekly chemistry news quiz, July 10
(21h)
HIV vaccine candidates reach milestone in primates
(1d)
China bets on AI to speed up science despite chip limits
(1d)
ACS Egypt to host Third International Conference on Chemical Sciences
(2d)
80-year-old US Navy asbestos study faces call for retraction
(2d)
A simpler way to make rotaxanes
(2d)
Delivering bad news
(2d)
Using AI songs to learn physical chemistry
(2d)
EPA moves to cut risks from PFAS in fertilizer, pans Biden-era analysis
(3d)
Business Watch: Anthropic launches Claude Science; AstraZeneca links with CSPC again
(3d)
This new stretchable battery harvests water from air
(3d)
Chemistry in Pictures: Fire and lightning
(3d)
Don’t forget about electricity when greening your chemistry lab
(3d)
Solstice to buy Element Solutions for $14.5 billion
(4d)
C&EN's Global Top 50 chemical firms for 2026
(4d)
The Pharma Letter
Padcev-Keytruda wins broader FDA approval in bladder cancer
(12h)
FDA thumbs up for Sanofi’s subcutaneous Sarclisa Escena
(16h)
Hansoh reports positive Phase III China data for GSK-partnered Ris-Rez in small cell lung cancer
(16h)
Chronic hepatitis C cases set to edge higher across major markets through 2035, says GlobalData
(16h)
NMPA reviews QMS for regulation of vaccine and drug GMP compliance
(17h)
PharmNovo secures capital ahead of Phase II study
(18h)
NICE draft guidance threatens access to Amgen lung cancer drug
(18h)
Russia to postpone "second-extra" rule for vital drugs during public procurements
(20h)
Natco Pharma announces $300 million South Africa expansion
(20h)
Forte’s FB102 achieves statistically-significant improvement in vitiligo
(20h)
Roche drops two Huntington’s programs after tominersen miss
(22h)
Amprion and Modality.AI work together on biomarkers project
(22h)
GSK exits Alector neurodegeneration alliance after trial failures
(22h)
Amprion and Modality.AI work together on biomarkers project
(22h)
Teva and Samsung Bioepis to commercialize Opuviz in Canada
(23h)
Fonseca Biosciences launches Xtoro for otitis externa
(23h)
Teva boosts biosimilars pipeline with Ocrevus licensing deal
(1d)
Dr Reddy's sees generic semaglutide supply disruption
(1d)
BioMed X and Boehringer expand XSeed Labs team
(1d)
China’s NMPA accepts BLA for Padcev in MIBC
(1d)
Targeted Oncology
FDA Accepts NDA for Varegacestat in Desmoid Tumors
(2d)
Oral CELMoD Golcadomide Advances in Relapsed FL
(2d)
Implementing a Bispecific Antibody Program in Community Oncology—Insights From the American Oncology Network
(2d)
The Evolution of Treatment Goals in Immune Thrombocytopenia
(2d)
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
(2d)
Oncologists Consider Treatment Duration and New Options in Progressive Desmoid Tumors
(3d)
Further MonumenTAL-3 Follow-Up Needed for Triplet Regimen in Relapsed Myeloma
(3d)
CMS Proposes Cut to 340B Drug Payments in 2027 Outpatient Rule
(3d)
Adagrasib Plus Cetuximab Falls Short in KRAS G12C–Mutated Colorectal Cancer
(3d)
FDA Rejects Manganese Chloride Tetrahydrate for Liver MRI in Renal Impairment
(3d)
Navigating the Nuances of Post-ESA Treatment in Lower-Risk MDS
(4d)
The Growing Rationale for Earlier Targeting of GPRC5D in Multiple Myeloma
(4d)
Botensilimab Plus Balstilimab Yields 33% OS Rate at 3 years in MSS mCRC
(4d)
FDA OKs ProstACT Trial Part 2 Protocol for Metastatic Prostate Cancer
(4d)
Molecular Subtype, Not Treatment Sequence, Drives Low-Grade Glioma Survival
(4d)
Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
(5d)
How a Virtual Behavioral Health Program Is Reaching Patients With Cancer Who Need It Most
(5d)
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
(6d)
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
(1w)
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
(1w)
MedWatch
Mikael Dolsten takes chair at AI company BenchSci after withdrawing from Novo Nordisk board race
(18h)
After years of delays: MagCath's female catheter greenlighted for sale in Europe
(19h)
Biotech CEO on new Novo Nordisk partnership: “This could be big”
(19h)
Danish Copli acquired by US company to help pharma firms avoid regulatory violations
(20h)
FDA criticizes Lundbeck: Websites are “false or misleading”
(21h)
Novo Nordisk’s Wimbledon play: Expanding brand beyond weight loss
(21h)
Novo Nordisk’s Wimbledon play: Expanding brand beyond weight loss
(21h)
Leo Pharma takes next step in bringing eczema treatment to children
(22h)
Moderna and the EU sign contract for RSV vaccines
(23h)
China adds Novo's semaglutide to list of critical medicines
(1d)
AstraZeneca signs potential USD 1.9bn deal with China's Sino
(1d)
Medtrace reaches last patient in phase III – chief exec now seeks new capital
(1d)
AstraZeneca's key phase 3 trial falls short
(1d)
Nordea sees bright future for Bavarian Nordic's vaccine sales
(2d)
Novo Nordisk launches once-weekly insulin treatment in India
(2d)
Novo Nordisk wins Singapore court battle over frozen funds
(2d)
US employers still reluctant to cover weight-loss drugs
(2d)
Bank of America looks favorably upon Demant's launch of Oticon Zeal
(2d)
Europe cannot talk about strategic autonomy and ignore the vaccine industry
(2d)
EMA steps up focus on women's health
(2d)
In The Pipeline
Chemical Onshoring of All Kinds
(1d)
Turning Down the Refinery Heat
(2d)
A Telomerase Inhibitor Revealed
(3d)
Behold the SpudCell
(4d)
Don't Minimize the Side Effects
(1w)
Speaking Up: Who Is, and Who Isn't
(2w)
Antibody-Drug Conjugates: Not Quite Worked Out Yet
(2w)
Here's a Ligand, Go Design a Protein
(2w)
Machine-Learning Mass Spec Data: Hmmm
(3w)
Covid-19 Vaccinations and the Heart
(4w)
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(4w)
A New Antibiotic Idea From An Old Source
(1mo)
Insights Into Idiopathic Pulmonary Fibrosis
(1mo)
Unusual Toxicity With a Protein Degrader Molecule
(1mo)
The Causes of Long Covid
(1mo)
Action! Action Now.
(1mo)
The Current Crisis: What's Happening to Science in America
(1mo)
Evaluating "Co-Scientist", a New AI Science System
(1mo)
That Methyl Methacrylate Tank
(1mo)
Reading the Labels on Mutant Mice
(1mo)
Pharmaphorum
Non-profit DNDi preps phase 3 trials for dengue antibody
(20h)
Bausch + Lomb drug fails in glaucoma, but a new use beckons
(21h)
Roche abandons two Huntington's drug candidates
(22h)
Bayer gets €3bn from Apollo for contraceptives unit stake
(23h)
Moderna's mResvia gets shot in the arm from EU contract
(1d)
Keenova eyes Xiaflex as first drug for plantar fibromatosis
(1d)
GSK ends dementia alliance with Alector after setbacks
(1d)
NICE aims to cut funding for Amgen lung cancer drug Lumykras
(1d)
AZ, Ionis hit by unexpected Wainua trial failure
(2d)
UK first in Europe to clear Boehringer's IPF drug Jascayd
(2d)
Aureka offers open-source AI module for drug discovery
(2d)
AZ pays $200m upfront for Sino Bio COPD drug
(2d)
EU seeks advice on Sanofi's response to mismarketing claim
(2d)
Otsuka's Voyxact faces rival as FDA okays Vera IgAN drug
(2d)
Kailera's big obesity reveal puts pressure on shares
(3d)
Obesity biotech Kalohexis files confidential IPO
(3d)
Island Pharma drug cleared for Bundibugyo Ebola use
(3d)
With measles cases rising, UK launches vaccination drive
(3d)
NICE backs NHS use of non-invasive endometriosis tests
(3d)
Vertex buys Crinetics for $10bn in endocrinology drive
(4d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3w)
Webinar: Learn how to accelerate the early stages of drug discovery
(3w)
Therapy enables 89% survival rate in myeloma patients
(3w)
Ulcerative colitis treatment shows best-in-class potential
(3w)
UK patients to benefit from approval of weight loss tablet
(3w)
Vertex presents new data on Casgevy in children
(3w)
DDW Highlights: 16 June 2026
(3w)
LXR inverse agonist shows promise in liver disease
(3w)
Guide: One solution – from R&D, to QC
(3w)
A potentially practice-changing advance in bile duct cancer
(3w)
Webinar: Consolidate multiple assays into a single, comprehensive AVA test
(3w)
JAK inhibitor for VEXAS syndrome gets orphan drug designations
(4w)
Whitepaper: How workflow scheduling software can answer the demands of automated labs
(4w)
PhoreMost advances brain cancer programme to trial
(4w)
Oriva appoints Arbat as CEO, advances endometriosis asset
(4w)
Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar
(4w)
This week in Drug Discovery (8 June – 12 June)
(4w)
Laverock reports positive data from oncology programmes
(4w)
GSK acquires Nuvalent and cancer therapy pipeline
(4w)
HIT Consultant
Health Payers Have Invested in Modern Data Infrastructure. Access Control Hasn’t Kept Up.
(1d)
The Technology Gap Holding Provider-Sponsored Health Plans Back
(1d)
Grounding Clinical AI in Evidence: The Critical Role of Human Oversight and Continuous Validation
(1d)
Beyond the Screen: How Telepsychiatry Must Evolve in theEra of Interventional Psychiatry
(1d)
Scaling Enterprise Imaging: IT Lessons from Digital Pathology
(1d)
AccurKardia and Wellysis Form Multi-Year Strategic Partnership to Deliver End-to-End Cardiac Monitoring
(1d)
Why Health Tech Leaders Need to Stop Setting Goals and Start Drawing Ladders
(2d)
KLAS Releases Global Hospital EHR Market Share 2026 Report: Purchasing Decisions Hit 5-Year Low
(2d)
IT Teams are the New Drivers of Healthcare Efficiency and Value
(3d)
What Produce Longevity Can Teach Us About Personalized Health Care
(4d)
KLAS Arch Collaborative Releases Clinician EHR Experience 2026 Impact Report
(2w)
Hera Raises $27M to Scale AI-Powered Senior Care Coordination
(2w)
ZS Impact Institute Releases 2026 Future of Health Report: AI and the Consumer-Led Care Revolution
(2w)
Hurone AI Licenses Mayo Clinic’s HOUSES Technology to Scale Personalized Cancer Navigation
(2w)
AMGA 2026 Survey: Provider Compensation Rises 4.3% as Medical Groups Face Sustainability Warning
(2w)
Beyond Chatbots: Agentic AI as the Operating System Transforming Patient Services
(2w)
Houston Methodist Partners with HealthLeap to Launch AI-Driven Clinical Screening Platform
(2w)
xCures Raises $46M to Turn Unstructured EHR Data Into Actionable Clinical Intelligence
(2w)
Upside Secures $20M to Scale AI-Driven Housing Stability Platform for Healthcare
(2w)
Innovaccer and AWS Announce Multi-Year Strategic Collaboration to Scale Agentic AI in Healthcare
(2w)
Insights: Pink Sheet
US FDA Proposes One Registration For Distributed Drug Manufacturing Networks
(10h)
US FDA Hiring Binge: CDER, CBER Report Q3 Bump, First Since Trump Administration Cuts
(11h)
Unpause? US FDA Posts 14 New CRLs After Temporary Halt
(14h)
Pink Sheet Podcast: Complete Response Letter And DTC Ad Regulations, Potential US FDA Reorg
(14h)
Recent And Upcoming US FDA Advisory Committee Meetings
(15h)
EMA Fast-Tracks Daraxonrasib In Test Run For New Phased Review Process
(16h)
‘Excited And Confident:’ PIC/S Builds Momentum For Harmonized E6(R3) Inspections
(16h)
Is There ‘Leeway’ For EU Countries To Extend Wastewater Directive Costs Beyond Pharma And Cosmetics?
(17h)
Japan Awards Global-First Reimbursement To Ishin’s Allostem, Heihe’s Risovalisib
(23h)
National Priority Voucher Critics Ask Why The US FDA Needs Another Expedited Review Pathway
(1d)
CMS Takes Aim At ‘Unnecessary’ Botulinum Toxin Use In Medicare
(1d)
Clinical Data The Latest Front As Congress Moves To Counter China’s Growing Pharma Clout
(1d)
EU JCA Reports For PharmaMar’s Zepzelca And Amgen’s Imdylltra Highlight PICO Number Discrepancy
(1d)
US FDA Begins Search For Cell, Gene Therapy Office Director
(1d)
Amgen To Appeal Against English Funding Rejection For Lumykras
(1d)
UK MHRA Inspectors Want The ‘Story’ Behind Clinical Trial Priorities, Not Just The List
(1d)
Indian Think Tank’s Pre-Grant Opposition Time Bar: Tighter Window Or Closed Door?
(1d)
China Doubles Down On Market Access Speed For Cell And Gene Therapies
(2d)
US FDA Moves To Eliminate ‘Adequate Provision’ For DTC Broadcast Ads
(2d)
Biosimilar Development Fees Dropped As US FDA And Industry Concluded BsUFA IV Negotiations
(2d)
BioXconomy
Germany doubles pharma rebates to curb costs
(15h)
Legislative changes alter GTN landscape
(20h)
Sandoz launches direct-to-patient drug platform
(20h)
Leo Cancer Care lands $65m Series D to bring upright proton platform to underserved communities
(22h)
Realizing Integrated Planning and Gross-to-Net
(1d)
Price cuts boosted PCSK9 inhibitor use in Medicare
(1d)
Platforms won’t power the next generation of clinical trials. AI ecosystems will.
(1d)
ACA insurers seek 14% hike for 2027 coverage
(1d)
High prior authorization rates drive MA exodus
(1d)
Regeneron to provide gene therapy for genetic hearing loss for free
(1d)
Sino lands second mega deal with AZ $2.1bn licensing agreement
(1d)
How the chief compliance officer can be an enterprise shaper
(2d)
Sponsors should leverage trial sites’ operational expertise, says AMRC
(2d)
Quebec tribunal ruling clarifies patient referral rules, but legal challenges loom for drugmakers
(2d)
MeiraGTx secures $400m to advance late=stage gene therapies
(2d)
EY says AI-driven supply chains can solve clinical trial distribution and complexity challenges
(3d)
Florida probes CVS model; OIG backs manufacturer diagnostics tests
(3d)
Biopharma firms make it a sizzling summer for legal and complianceappointments
(3d)
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial
(3d)
Vertex makes largest ever acquisition with $10bn Crinetics deal
(3d)
BioCentury
With first clinical data due next year, Scribe to test IPO market: Finance Report
(7h)
FDA resumes CRL releases, citing ‘commitment to transparency’
(7h)
Perspective — siRNAs are better than ASOs
(8h)
2Q26 Wrap: Income inequality
(9h)
Can M&A momentum carry biotech through year-end?
(9h)
Roivant’s Gline: From spin-cos to commercial conviction
(1d)
New CEO appointments include Idorsia, Arrakis leaders
(1d)
Science Spotlight: Actionable pathways for cachexia and radioresistance in lung cancer
(1d)
Ionis’ ATTR-CM miss: Were overlapping mechanisms or the modality to blame?
(1d)
Biotech in Burnham’s Britain
(1d)
ParcelBio: Engineering potent and durable mRNA for in vivo CAR Ts
(2d)
Race to cure HBV moves to targeting the reservoir
(2d)
FDA to shore up legal basis for CRL disclosures as it pauses new releases
(2d)
Big week for M&A brings three rare disease takeouts: Deals Report
(3d)
Takeda’s orexin program: The hits, the misses and the payoff
(3d)
Makary era reversals continue with another ultra-rare U-turn by FDA
(3d)
Vertex further diversifies with ‘fifth pillar’ via $10B Crinetics acquisition
(3d)
CHRNA7 viability uncertain after Neuphoria’s Phase II Alzheimer’s miss
(4d)
With $1.1B Myricx buy, Novartis takes plunge into ADCs
(4d)
Novartis’ ADC gambit & regulation as catalyst for U.K. biotech — a BioCentury podcast
(4d)
SCRIP
Gilead’s Biggest Buys Balance Drug Candidate Needs With Platform Desires
(10h)
Roche Pulls Plug On Two Antisense Oligonucleotide Programs In Huntington’s
(10h)
Pharma At The Midyear: Taking Stock Of Financial Forecasts
(11h)
LEO Reports Phase II Pediatric Data As Tralokinumab Advances Through Phase III
(16h)
Bayer Break-Up Rumors Revived After €3bn Apollo Pact
(18h)
Executives On The Move: Eight CEOs And Three CFOs Among This Week’s Changes
(20h)
Global Phase III Trial For Serum Institute/Visterra’s Dengue Candidate Sharing Voyxact Platform
(22h)
Mega-Round Surge Leads Big Q2 Venture Funding Boom
(1d)
InxMed’s Ifebemtinib Moves Ahead Amid Positive Phase II NSCLC Combo Data
(1d)
Tarsus Will Move Into Chronic Retinal Disease With iRenix Takeout
(1d)
Dr Reddy’s API Snag To Hit Semaglutide Supplies, CEO Expects Fix Later This Year
(1d)
GSK Bids Farewell To Alector Dementia Deal
(1d)
BioBytes: AI-Related Deals In Q2 ‘26
(1d)
AstraZeneca’s Trial-Design Halo Slips As Wainua Fails Phase III In ATTR-CM
(2d)
Novo Nordisk Launches Once-Weekly Insulin Awiqli In India To Treat Type 1, Type 2 Diabetes
(2d)
Alchemab Flies Flag For UK Biotechs With Government Backing
(2d)
Blackstone Fills Financing Niche, Backing Big Pharma’s Rapidly Growing Pipelines
(2d)
Chemomab, Scipher Bet On Taking AI-Powered Precision Medicine Into Immunology
(2d)
Insilico’s Bold Move To Take AI-Discovered Asset Into Phase III
(2d)
Vera Edges Vertex In IgAN Race As FDA Approves Trutakna
(2d)